

Table S1. Objective response rate in prespecified subgroups.

Prespecified subgroups	n	Objective response rate, % (95% CI)
Gender		
Male	115	20.0 (13.1–28.5)
Female	31	9.7 (2.0–25.8)
Tumor histology		
Squamous cell carcinoma	66	25.8 (15.8–38.0)
Non-squamous cell carcinoma	80	11.3 (5.3–20.3)
Line of previous treatment		
<2	111	17.1 (10.6–25.4)
≥2	35	20.0 (8.4–36.9)
Brain metastases		
Yes	19	0
No	127	20.5 (13.8–28.5)
<i>EGFR</i> mutation status		
Wildtype- <i>EGFR</i>	140	18.6 (12.5–26.0)
Mutant- <i>EGFR</i> *	6	0
ECOG performance status		
0	8	25.0 (3.2–65.1)
1	138	17.4 (11.5–24.8)
Age		
<65	108	17.6 (10.9–26.1)
≥65	38	18.4 (7.7–34.3)
PD-L1 expression		
TPS<1%	74	12.2 (5.7–21.8)
TPS≥1%	72	23.6 (14.4–35.1)

ECOG, Eastern Cooperative Oncology Group; TPS, tumor proportion score. *

One patient in PD-L1 ≥50% group were re-classified into PD-L1<1% group after PD-L1 expression re-evaluation.